Rozrolimupab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRozrolimupab
Drug Alias NameSymphoglobulin-DAnti-rhesus D immunoglobulin GsAnti-rhesus D polyclonal antibodiesSym-001Anti-RhD +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionBlood group Rh(D) polypeptide inhibitors
TargetsBlood group Rh(D) polypeptide
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUkraine +[12] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSymphogen A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSymphogen A/S
Active IndicationsN/A
Inactive IndicationsPurpura, Thrombocytopenic, Idiopathic

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG